Last reviewed · How we verify
Innovator infliximab
At a glance
| Generic name | Innovator infliximab |
|---|---|
| Also known as | Remicade |
| Sponsor | Diakonhjemmet Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The NOR-SWITCH Study (PHASE4)
- "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Innovator infliximab CI brief — competitive landscape report
- Innovator infliximab updates RSS · CI watch RSS
- Diakonhjemmet Hospital portfolio CI